{'fraction_non_alphanumeric': 0.020394289598912305, 'fraction_numerical': 0.011556764106050306, 'mean_word_length': 4.959514170040486, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
EFFECT OF THE NEW STEROID DRUG GESTOBUTANOIL FOR HORMONE REPLACEMENT THERAPY OF GESTAGENOUS INSUFFICIENCY ON THE DEVELOPMENT OF FETUS AND OFFSPRING IN EXPERIMENTS ON RATS

A study of the embryo- and fetotoxic effects registered in the antenatal and postnatal periods of development after the intragastric administration of Gestobutanoil in two doses (equitherapeutic and 10 times higher) has been performed. It has been found that the introduction of gestagen Gestobutanoil in both doses did not affect the body weight of pregnant animals, which continued to increase progressively during pregnancy. The embryotropic effect of gestagen was revealed to be dose-dependent. The introduction of gestagen in a dose of 0.25 mg / kg (calculated equitherapeutic dose) had no adverse effect on the development of the embryo and fetus of rats. The gestagen in a dose of 2.5 mg / kg (10 equitherapeutic dose) had a negative effect on the course of pregnancy, which has been manifested by a statistically significant increase in preimplantation death and total fetal mortality, as well as a statistically significant decrease in the number of fetuses. It has been shown that intragastric administration of Gestobutanoil in doses of 0.25 and 2.5 mg / kg to female rats from the 6th to the 19th days of pregnancy did not adversely affect the early development of the first generation offspring (postnatal mortality, body mass dynamics, and development of rats’ sensory-motor reflexes).